Acute Intermittent Porphyria
Abdominal pain is the most common complaint in acute intermittent porphyria. In addition, some of the following symptoms occur with varying frequency: pain in the arms and leg, generalized weakness, vomiting, confusion, constipation, tachycardia, fluctuating blood pressure, urinary retention, psychosis, hallucinations, and seizures. The muscle weakness may progress to respiratory paralysis, necessitating artificial respiration. Porphobilinogen is elevated during the attack but may be consistently high in some patients. Urine may exhibit a purple-red color. Unlike other forms of porphyria, sun sensitivity is not present in this type.
Variegate porphyria is characterized by abrasions, blisters, and erosions of the skin which are commonly seen during the second and third decade. These lesions tend to heal slowly, often leaving pigmented or slightly depressed scars. The patients experience sensitivity to light and fragility of skin exposed to the sun. Although in many patients manifestations remain limited to the skin, episodes similar to those of acute porphyria are not uncommon. Therefore, the symptoms, drugs, precautionary measures, and treatment described for acute intermittent porphyria are applicable to variegate porphyria.
The large amounts of coproporphyrin present in hereditary coproporphyrin makes the patient sensitive to sunlight, but skin disease is rarely severe in this type of porphyria. Clinically it resembles variegate porphyria except that a larger percentage of affected individuals exhibit few symptoms. Other symptoms are similar to those listed for acute intermittent porphyria.
Protoporphyria can have mild to severe light sensitivity and burning on exposure to the sunlight. Usually, the symptoms subside in twelve to twenty-four hours and heal without significant scarring or discoloration to the skin. The skin lesions may also progress to a chronic stage persisting for weeks and healing with a superficial scar. These manifestations generally begin in childhood. They are more severe in the summer and can recur throughout life. Affected skin, at times, exhibits the fragility or blister formation seen in other photosensitizing types of porphyria. Hepatobiliary dysfunction may be associated with significant liver damage.
Porphyria Cutanea Tarda
In porphyria cutanea tarda, exposed skin shows abnormalities similar to those found in variegate porphyria. They range from slight fragility of the skin to persistent scarring and disfiguration. Due to fragility of the skin, minor trauma may induce blister formation. Areas of increased and decreased pigment content may be noted on the skin. Blistering of light exposed skin and increased hair growth, especially on the face, are also characteristic.
Congenital Erythropoietic Porphyria
This is a very rare disease with approximately 150 patients reported in the world. congenital erythropoietic porphyria is often manifested shortly after birth with dark urine and sunlight sensitivity causing blistering and skin fragility. Later, brownish, fluorescent teeth, increased hair growth, and pronounced scarring may occur. In some cases, loss of fingers and toes and cartilage from ears or nose may be noted.
ALA-D porphyria symptoms usually arise from effects on the nervous system and/or the skin. Sometimes, the cause of the nervous system symptoms is not clear. Skin manifestations include burning, blistering, and scarring of the sun exposed areas. The disease usually manifests after puberty, and more commonly occurs in women. The most common symptom is severe abdominal pain. Other characteristics are nausea, vomiting, rapid heart rate, increased blood pressure, confusion and/or seizures, and the passing of ALA (delta- aminolevulinic acid) in the urine.
The porphyrias are a group of inherited disorders caused by deficiencies of enzymes needed in particular steps in the synthesis of the heme molecule. Of the seven distinct disorders that make up the porphyrias, four are transmitted as autosomal dominant traits, two are transmitted as autosomal recessive traits and one is transmitted in a more complex manner.
The following summarizes the mode of inheritance and the location of the genetic abnormality associated with each specific type of porphyria:
ALA-D porphyria; autosomal recessive; 9q34
Acute intermittent porphyria; autosomal dominant;11q24.1-q24.2
Hereditary coproporphyria; autosomal dominant; 3q12
Variegate porphyria; autosomal dominant; 1q21-23
Congenital erythropoietic porphyria; autosomal recessive; 10q25.2-q26.3
Porphyria cutanea tarda; complex genetic transmission; 1p34
Erythropoietic protoporphyria; autosomal dominant; 18q21.3
Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22 and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated “p” and a long arm designated “q”. Chromosomes are further sub-divided into many bands that are numbered. For example, “chromosome 1p34” refers to band 34 on the short arm (p) of chromosome 1. The numbered bands specify the location of the thousands of genes that are present on each chromosome.
Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.
Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.
All individuals carry a few abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.
The prevalence of porphyria remains unknown, but clinicians suggest that a range of 1 per 500-50,000 of population is probable. Some forms of porphyria are more common in specific populations including, for example, in Finland.
The basic defect cannot presently be treated, but significant effort is being directed toward treating the underlying mechanisms that cause symptoms. Porphyria is diagnosed through blood, urine, and stool tests.
Some people who are identified as having inherited porphyria do not have symptoms. It is important for those people, as well as for those who have symptoms, to be aware of preventive measures that may help them avoid episodes of porphyria symptoms. These preventive measures include avoidance of certain drugs and alcohol for some types of porphyria. For some people, they may also include avoidance of exposure to sunlight because sun sensitivity can occur with some types of porphyria. More specific information on these preventive measures is available from the American Porphyria Foundation (see Resources section of this report).
Some of the drugs that affected individuals may need to avoid include barbiturates, tranquilizers, birth control pills, sedatives, and alcohol.
An orphan drug formerly known as Hemin, now called Panhematin (hemin for injection), is approved for use as a treatment for various forms of porphyria and is administered intravenously. It is extremely potent, and its use typically follows a period of glucose therapy that has not produced the desired results. For information, contact the sponsor:
Four Parkway North
Deerfield, IL 60015
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Information about current research on porphyria also is available from the American Porphyria Foundation. (See contact information and web site in the Resources section of this report.)
Recombinant human porphobilinogen deaminase (rhPBGD or Porphozom) was granted orphan drug designation on September 9, 2002, for the treatment of acute intermittent porphyria attacks. This drug is being developed by Zymenex, formerly known as HemeBiotech, a Scandinavian biotechnology company. Patients are being recruited (August 2005) for a study to help determine the safety and effectiveness of Porphozom for treatment of acute attacks. The study is being conducted by Dr. Herbert Bonkovsky at the University of Connecticut in Farmington and Dr. Karl Anderson at the University of Texas in Galveston.
For information, contact Desiree Lyon at the American Porphyria Foundation at email@example.com or (713) 266-9617.
Several other products have been granted orphan drug designation by the FDA for the investigational treatment of the porphyrias. For information, see the FDA Orphan Products and Designations List, or contact the American Porphyria Foundation.
A clinical trial, cosponsored by the National Center for Research Resources and the University of Texas Medical Branch in Galveston, is currently recruiting up to 25 patients. The trial is designed to characterize enzyme defects in patients with known or suspected porphyria and in their family members. Some participants will be selected to participate in other research involving porphyria, and analysis of samples taken from patients and/or their families will help in the study of specific mutations.
For further information contact:
Karl E. Anderson, MD
University of Texas Medical Branch
Galveston, TX 77555-0209
RareConnect offers a safe patient-hosted online community for patients and caregivers affected by this rare disease. For more information, visit www.rareconnect.org.
Anderson KE. Acute Intermittent Porphyria, ALA-Dehydratase-Deficient Porphyria, Congenital Erythropoietic Porphyria, Porphyria Cutanea Tarda, Variegate Porphyria and Hereditary Coproporphyria. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:490-95.
Mathews-Roth MM. Erythropoietic Porphyria. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:495-96.
Anderson KE, Sassa S, Bishop DF, et al. Disorders of Heme Synthesis. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The Metabolic Molecular Basis of Inherited Disease. 8th ed. McGraw-Hill Companies. New York, NY; 2001:3024-62.
Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:185-200.
Berkow R, ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:933-36.
Menkes JH, Pine Jr JW, et al., eds. Textbook of Child Neurology. 5th ed. Williams & Wilkins. Baltimore, MD; 1995:129.
Foran SE, Abel G. Guide to the porphyrias. A historical and clinical perspective. Am J Clin Pathol. 2003;119 Suppl:S86-93.
Lecha M, Herrero C, Ozalla D. Diagnosis and treatment of the hepatic porphyrias. Dermatol Ther. 2003;16:65-72.
Murphy GM. Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther. 2003;16:57-64.
Downey DC. The porphyrin pathway: the final common pathway? Med Hypotheses. 2002;59:615-21.
Nordmann Y, Puy H. Human hereditary hepatic porphyrias. Clin Chim Acta. 2002;325:17-37.
Aggarwal N, Bagga R, Sawhney H, et al. Pregnancy with acute intermittent porphyria: a case report and review of the literature. J Obstet Gynaecol Res. 2002;28:160-62.
Ahmed I. Childhood porphyrias. Mayo Clin Proc. 2002;77:825-36.
Badminton MN, Elder GH. Management of acute and cutaneous porphyrias. Int J Clin Pract. 2002;56:272-78.
Lambrecht RW, Bonkovsky HL. Hemochromatosis and porphyria. Semin Gastrointest Dis. 2002;13:109-19.
Sassa S, Akagi R, Nishitani C, et al. Late-onset porphyrias: what are they? Cell Mol Biol (Noisy-le-grand). 2002;48:97-101.
Murphy GM. Diseases associated with photosensitivity. J Photochem Photobiol B. 2001;64.
Elder GH, Hift RJ. Treatment of acute porphyria. Hosp Med. 2001;62:422-25.
Deacon AC, Elder GH. ACP Best Practice No 165: frontline tests for the investigation of suspected porphyria. J Clin Pathol. 2001;54:5000-07.
Shaw PH, Mancini AJ, McConnell JP, et al. Treatment of congenital erythropoietic porphyria in children by allogenic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant. 2001;27:101-05.
FROM THE INTERNET
About Porphyria. American Porphyria Foundation. 2003. 10pp.
Information for Patients. PORPHYRIA BOOKLET. 2003.
A Guide to Porphyria. Canadian Porphyria Foundation, Inc.
Porphyria. MedlinePlus. Medical Encyclopedia. Page last updated: 05 January 2004. 4pp.
Porphyria. National Digestive Diseases Information Clearinghouse. March 2003. 4pp.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100